Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (367)	1/27/2000 11:49:00 AM
From: Henrik	Read Replies (1) \| Respond to of 743

Zaxis International Inc. Announces Multi-Year Supply Agreement With Visible Genetics Inc. During January this stock has been trading between 13/16 and $4. Currently around $2 7/8 with increased volume. Anyone on this thread following the stock or understand the financial potential of ZAXS' technology ? Cheers, Henrik ========================================================== biz.yahoo.com HUDSON, Ohio--(BUSINESS WIRE)--Jan. 26, 2000--Zaxis International Inc. (OTCBB:ZAXS - news) and Visible Genetics Inc. (Nasdaq:VGIN - news) today announced the signing of a multi-year agreement under which Zaxis International will supply Visible Genetics with the SureFill(TM) gel cartridge used with their OpenGene(TM) Automated DNA Sequencing System. ``This contract is another confirmation of our plan to become the number one supplier of consistent, reliable and the highest quality DNA gels for the leading manufacturers of high performance automated DNA sequencing systems,' said John Hrobsky, president and CEO of Zaxis International. In addition to providing proprietary products to Visible Genetics, Zaxis will provide technical assistance and product development support. David Gibbons, vice president of product support & development for Visible Genetics, stated, ``We are pleased to secure our source of supply for our OpenGene(TM) System and to be associated with a high quality manufacturer like Zaxis International.' The OpenGene(TM) System employs proprietary stratified DNA testing and single-tube, single step sequencing methods which reduce the time and cost involved in identifying clinically important genetic information. Zaxis International Inc. is a biotechnology company that produces electrophoresis gels for testing blood proteins and various genetic compounds. Zaxis produces these gels for the research and clinical markets. The company is a leader in this high growth market and is poised to take advantage of its leading edge technology. Statements in this press release that relate to matters that are not historic fact are forward-looking statements that involve market risks and uncertainties including, but not limited to, the ability of Zaxis International to develop and commercialize the products that are subject to this program and other risks and uncertainties in the company's Securities and Exchange filings.

To: RWReeves who wrote (367)	1/28/2000 6:51:00 PM
From: Mike McFarland	Respond to of 743

Oh yeah, stoic--I watched ten percent get chopped right off the top today. Until the market opened I was sporting an account at an all time high (with the exception of an intraday high on Tuesday as all my stocks happened to be at the ask for one wonderful moment in time) <g> Little letter g is for a forced smile. Small wonders only down 2%, and Blind Squirrel only off five, you fellas held up well. Doesn't look like I'm going to be able to claim 3X for the month anymore, and Monday is still January...boo hoo.

To: RWReeves who wrote (367)	1/28/2000 11:29:00 PM
From: Cheryl Galt	Read Replies (2) \| Respond to of 743

I've enjoyed checking out your small wonders. But just a cautionary note about AIMM Autoimmune (AIMM) fell on hard times after their Ph III for Colloral failed last September. What's left is two part-time staffers and whatever's left of $8M cash in the bank. The tail end of its SI thread describes the current end-stage stock gyrations, as traders respond to rumors. (Might someone be buying what's left?????) Message 12114251 A Nov 5 release gives details of the sad story: biz.yahoo.com o some on-going trials continue, at various sites o 24 of 26 positions eliminated; $650,000 in severance costs o the two remaining staffers are on part-time o the facility lease was not renewed, o all parties involved with the open label trials were notified of their termination o All bulk manufacturing process equipment has been dismantled for storage. o All data has been archived in hard copy format. o The Company's network and phone systems have been disposed. Wear gloves if you play with this knife ... Cheryl